![FDA, FTC and DOJ Enforcement of Medical Device Regulations FDA, FTC and DOJ Enforcement of Medical Device Regulations](https://www.fdanews.com/ext/resources/Book-Covers-2/BFFDEMDR-COVER.png?height=200&t=1685733565&width=200)
Home » CFDA Approves Venus Medtech's TAVR Device
CFDA Approves Venus Medtech's TAVR Device
May 1, 2017
China–based Venus Medtech has received approval from the China Food and Drug Administration (CFDA) for its Venus A-valve.
The company’s transcatheter aortic valve system, Venus A-valve, provides a less invasive treatment solution for inoperable and high-risk patients.
The study showed the implantation success rate was 95 percent and the 30-day all-cause mortality was 5 percent.
The company will launch a global trial for the third generation TAVR device at the end of 2017. — Cynthia Jessup
Upcoming Events
-
21Oct